<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182882</url>
  </required_header>
  <id_info>
    <org_study_id>1020.10</org_study_id>
    <nct_id>NCT02182882</nct_id>
  </id_info>
  <brief_title>Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy People</brief_title>
  <official_title>Efficacy of Ginsana in Improving Half -Time Hemoglobin Re-oxygenation in Recreational Sportspeople: a Double Blind, Placebo Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the efficacy of ginsana in improving half-time hemoglobin re-oxygenation in&#xD;
      healthy, recreational sportspeople and to assess the safety of the product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <primary_completion_date type="Actual">October 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in half-time hemoglobin re-oxygenation by Near InfraRed Spectroscopy (NIRS) methodology</measure>
    <time_frame>Baseline, day 84 post first drug dispense</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in half-time hemoglobin re-oxygenation by NIRS methodology</measure>
    <time_frame>Baseline, day 21, 42 and 63 post first drug dispense</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum endurance time</measure>
    <time_frame>up to day 84 post first drug dispense</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in respiratory threshold</measure>
    <time_frame>Baseline, up to day 84 post first drug dispense</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in thiobarbituric acid (TBARS)</measure>
    <time_frame>Baseline, up to day 84 post first drug dispense</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glutathion superdismutase / glutathion superdismutase oxidised (GSA/GSSG)</measure>
    <time_frame>Baseline, up to day 84 post first drug dispense</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GINSANA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GINSANA</intervention_name>
    <arm_group_label>GINSANA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female volunteers between 18 and 40 years old&#xD;
&#xD;
          -  Females must test negative for pregnancy&#xD;
&#xD;
          -  Recreational athletes according to the american college of sports medicine (ACSM)&#xD;
             definition&#xD;
&#xD;
          -  Familiar with the cycle ergometer exercise methodology&#xD;
&#xD;
          -  Written inform consent according to good clinical practice (GCP) and local regulations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-treatment (less than 2 weeks prior to inclusion in this trial) and/or concomitant&#xD;
             treatment with any drug that any drug that could have influence the trail methodology&#xD;
&#xD;
          -  Alcohol and drug abuse (as defined in Diagnostic and Statistic Manual IV( DSM-IV)) per&#xD;
             subject verbal report&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Known hypertension&#xD;
&#xD;
          -  Known hypercholesterolemia (moderate/severe)&#xD;
&#xD;
          -  Female volunteers taking oral or injectable contraceptives&#xD;
&#xD;
          -  Female volunteers of child bearing potential not using adequate means of birth&#xD;
             control, other than contraceptive pills [intrauterine devices (IUDs)]&#xD;
&#xD;
          -  Pregnancy and/or lactation&#xD;
&#xD;
          -  Liver and/or renal disease and/or vascular disease&#xD;
&#xD;
          -  Relevant allergy or known hypersensitivity to the investigational drug or its&#xD;
             excipients&#xD;
&#xD;
          -  Participation in another clinical trial within the last 4 weeks and concurrent&#xD;
             participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1020/1020.10_U00-0117.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 4, 2014</last_update_submitted>
  <last_update_submitted_qc>July 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

